Literature DB >> 30236766

Right lobe split liver graft versus whole liver transplantation: A systematic review by updated traditional and cumulative meta-analysis.

Paschalis Gavriilidis1, Keith J Roberts2, Daniel Azoulay3.   

Abstract

INTRODUCTION: Advancements in surgical techniques and experience of donor-recipient pairing has led to a wider use of right split liver grafts in adults. An update meta-analysis was conducted to compare right split liver graft (RSLG) and whole liver transplantation (WLT) using traditional and cumulative approaches.
METHODS: Databases were searched for relevant articles over the previous 20 years (MEDLINE, Embase, Cochrane Library, and Google Scholar). Meta-analyses were performed using both fixed and random effects models. Patient and graft survival were obtained using the inverse variance hazard ratio method.
RESULTS: Donors were significantly younger in the RSLG group than in the WLT group (MD = -12.06 [-16.29 to -7.83]; P < .001). In addition, the model for end-stage liver disease (MELD) score was significantly lower in the RSLG group than in the WLT group (MD = -2.45 [-4.61 to -.28]; P = .03). However, cold ischaemia time was significantly longer by 1 h in the RSLG group than in the WLT group (MD = 57 [20.63-92.73]; P = .002). Overall biliary, vascular, and outflow tract complications and hepatic artery thrombosis were significantly lower in the WLT group than in the RSLG group (odds ratio [OR] = 1.75 [1.35-2.27], P < .001; OR = 1.91 [1.37-2.65], P = .006; Peto OR = 1.83 [1.19-2.82], P = .006; and Peto OR = 2.07 [1.39-3.10], P = .004, respectively). However, no difference in patient and graft survival was noted between the two cohorts.
CONCLUSIONS: Although the RSLG group had a higher postoperative complication rate than the WLT group, equal patient and graft survival benefits were observed.
Copyright © 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Split liver graft; Split liver transplant; Whole liver transplantation

Mesh:

Year:  2018        PMID: 30236766     DOI: 10.1016/j.dld.2018.08.025

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  5 in total

1.  Adult split liver transplantation: A PRISMA-compliant Chinese single-center retrospective case-control study.

Authors:  Lingxiang Kong; Tao Lv; Jian Yang; Li Jiang; Jiayin Yang
Journal:  Medicine (Baltimore)       Date:  2020-12-18       Impact factor: 1.817

2.  Liberal Use of Interposition Grafts for Arterial Reconstruction Is Safe and Effective in Adult Split Liver Transplantation.

Authors:  Ngee-Soon Lau; Ken Liu; Abdullah Almoflihi; Josephine Xu; Geoffrey McCaughan; Michael Crawford; Carlo Pulitano
Journal:  Transplant Direct       Date:  2021-07-23

3.  Is it safe to expand the indications for split liver transplantation in adults? A single-center analysis of 155 in-situ splits.

Authors:  Ngee-Soon Lau; Mark Ly; Ken Liu; Avik Majumdar; Simone I Strasser; Raaj K Biswas; Geoffrey W McCaughan; Michael Crawford; Carlo Pulitano
Journal:  Clin Transplant       Date:  2022-04-26       Impact factor: 3.456

4.  Prognosis of Split Liver Transplantation Compared with Whole Liver Transplantation in Adult Patients: Single-center Results under the Korean MELD Score-based Allocation Policy.

Authors:  Gil Chun Park; Shin Hwang; Gi Won Song; Dong Hwan Jung; Tae Yong Ha; Chul Soo Ahn; Deok Bog Moon; Ki Hun Kim; Young In Yoon; Woo Hyoung Kang; Hwui Dong Cho; Jin Uk Choi; Minjae Kim; Byeong Gon Na; Sang Hoon Kim; Sung Gyu Lee
Journal:  J Korean Med Sci       Date:  2020-09-21       Impact factor: 2.153

5.  Fates of retained hepatic segment IV and its prognostic impact in adult split liver transplantation using an extended right liver graft.

Authors:  Yong-Kyu Chung; Shin Hwang; Chul-Soo Ahn; Ki-Hun Kim; Deok-Bog Moon; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Gil-Chun Park; Young-In Yoon; Woo-Hyoung Kang; Hwui-Dong Cho; Jin Uk Choi; Minjae Kim; Sang Hoon Kim; Byeong-Gon Na; Sung-Gyu Lee
Journal:  Ann Surg Treat Res       Date:  2021-06-30       Impact factor: 1.859

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.